» Articles » PMID: 33027952

Copper Complexes As Anticancer Agents Targeting Topoisomerases I and II

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2020 Oct 8
PMID 33027952
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Organometallics, such as copper compounds, are cancer chemotherapeutics used alone or in combination with other drugs. One small group of copper complexes exerts an effective inhibitory action on topoisomerases, which participate in the regulation of DNA topology. Copper complexes inhibitors of topoisomerases 1 and 2 work by different molecular mechanisms, analyzed herein. They allow genesis of DNA breaks after the formation of a ternary complex, or act in a catalytic mode, often display DNA intercalative properties and ROS production, and sometimes display dual effects. These amplified actions have repercussions on the cell cycle checkpoints and death effectors. Copper complexes of topoisomerase inhibitors are analyzed in a broader synthetic view and in the context of cancer cell mutations. Finally, new emerging treatment aspects are depicted to encourage the expansion of this family of highly active anticancer drugs and to expend their use in clinical trials and future cancer therapy.

Citing Articles

Yaravirus brasiliense genomic structure analysis and its possible influence on the metabolism.

Nunes-Alves A, Abrahao J, Farias S Genet Mol Biol. 2025; 48(1):e20240139.

PMID: 39918235 PMC: 11803573. DOI: 10.1590/1678-4685-GMB-2024-0139.


Formation and evaluation of doxorubicin and cromoglycate metal-organic framework for anti-cancer activity.

Abu Saleem E, Lafi Z, Shalan N, Alshaer W, Hamadneh I Nanomedicine (Lond). 2025; 20(5):467-479.

PMID: 39888613 PMC: 11875491. DOI: 10.1080/17435889.2025.2459059.


Anticancer potential of copper(i) complexes based on isopropyl ester derivatives of bis(pyrazol-1-yl)acetate ligands.

Pellei M, Santini C, Caviglia M, Del Gobbo J, Battocchio C, Meneghini C RSC Med Chem. 2024; 16(2):849-861.

PMID: 39618961 PMC: 11605304. DOI: 10.1039/d4md00610k.


The Role of STING-Mediated Activation of Dendritic Cells in Cancer Immunotherapy.

Ribeiro A, Neuper T, Horejs-Hoeck J Int J Nanomedicine. 2024; 19:10685-10697.

PMID: 39464674 PMC: 11512692. DOI: 10.2147/IJN.S477320.


Strong anticancer activity of copper(ii) and zinc(ii) complexes containing naturally occurring lapachol: cellular effects in ovarian A2780 cells.

Stocchetti S, Vanco J, Belza J, Dvorak Z, Travnicek Z RSC Med Chem. 2024; .

PMID: 39371430 PMC: 11451940. DOI: 10.1039/d4md00543k.


References
1.
Chen J, Huang Y, Liu G, Afrasiabi Z, Sinn E, Padhye S . The cytotoxicity and mechanisms of 1,2-naphthoquinone thiosemicarbazone and its metal derivatives against MCF-7 human breast cancer cells. Toxicol Appl Pharmacol. 2004; 197(1):40-8. DOI: 10.1016/j.taap.2004.02.004. View

2.
Pommier Y, Leo E, Zhang H, Marchand C . DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010; 17(5):421-33. PMC: 7316379. DOI: 10.1016/j.chembiol.2010.04.012. View

3.
Bower J, Zhou Y, Zhou T, Simpson D, Arlander S, Paules R . Revised genetic requirements for the decatenation G2 checkpoint: the role of ATM. Cell Cycle. 2010; 9(8):1617-28. PMC: 3096717. DOI: 10.4161/cc.9.8.11470. View

4.
Zakharenko A, Dyrkheeva N, Lavrik O . Dual DNA topoisomerase 1 and tyrosyl-DNA phosphodiesterase 1 inhibition for improved anticancer activity. Med Res Rev. 2019; 39(4):1427-1441. DOI: 10.1002/med.21587. View

5.
Afzal M, Al-Lohedan H, Usman M, Tabassum S . Carbohydrate-based heteronuclear complexes as topoisomerase Iα inhibitor: approach toward anticancer chemotherapeutics. J Biomol Struct Dyn. 2018; 37(6):1494-1510. DOI: 10.1080/07391102.2018.1459321. View